| Type | Title | Date Released | |
|---|---|---|---|
4 | Heshmatpour Amir F (Reporting) New | ||
8-K | NeOnc Reports Third Quarter 2026 Financial Results and Recent Clinical Progress | ||
10-Q | Form 10-Q | ||
8-K | NeOnc Technologies to Present Data from NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology | ||
8-K | Three-Year-Old Brain Tumor Patient Shows Early Improvement After Compassionate-Use NEO100 Treatment in Abu Dhabi | ||
3 | ALABEDIN ALI MOHAMMAD AHMAD MOHAMMAD (Reporting) | ||
8-K | NeOnc Technologies Appoints Ali Alabedin to Board of Directors | ||
8-K | NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212 | ||
8-K | NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution | ||
4 | GARNETT KEITHLY (Reporting) | ||
8-K | NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results | ||
4 | Heshmatpour Amir F (Reporting) |
